Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic Evaluation

被引:0
作者
Padraig Dixon
George Davey Smith
Stephanie von Hinke
Neil M. Davies
William Hollingworth
机构
[1] University of Bristol,School of Social and Community Medicine
[2] MRC Integrative Epidemiology Unit at the University of Bristol,School of Economics, Finance and Management
[3] University of Bristol,undefined
来源
PharmacoEconomics | 2016年 / 34卷
关键词
Healthcare Cost; Instrumental Variable; Causal Effect; Exclusion Restriction; Mendelian Randomization;
D O I
暂无
中图分类号
学科分类号
摘要
Accurate measurement of the marginal healthcare costs associated with different diseases and health conditions is important, especially for increasingly prevalent conditions such as obesity. However, existing observational study designs cannot identify the causal impact of disease on healthcare costs. This paper explores the possibilities for causal inference offered by Mendelian randomization, a form of instrumental variable analysis that uses genetic variation as a proxy for modifiable risk exposures, to estimate the effect of health conditions on cost. Well-conducted genome-wide association studies provide robust evidence of the associations of genetic variants with health conditions or disease risk factors. The subsequent causal effects of these health conditions on cost can be estimated using genetic variants as instruments for the health conditions. This is because the approximately random allocation of genotypes at conception means that many genetic variants are orthogonal to observable and unobservable confounders. Datasets with linked genotypic and resource use information obtained from electronic medical records or from routinely collected administrative data are now becoming available and will facilitate this form of analysis. We describe some of the methodological issues that arise in this type of analysis, which we illustrate by considering how Mendelian randomization could be used to estimate the causal impact of obesity, a complex trait, on healthcare costs. We describe some of the data sources that could be used for this type of analysis. We conclude by considering the challenges and opportunities offered by Mendelian randomization for economic evaluation.
引用
收藏
页码:1075 / 1086
页数:11
相关论文
共 249 条
[1]  
Doshi JA(2006)Analyses of cost data in economic evaluations conducted alongside randomized controlled trials Value Health. 9 334-340
[2]  
Glick HA(2015)A systematic review of research guidelines in decision-analytic modeling Value Health. 18 512-529
[3]  
Polsky D(2014)Decomposing growth in spending finds annual cost of treatment contributed most to spending growth, 1980–2006 Health Aff (Millwood). 33 823-831
[4]  
Peñaloza Ramos MC(2012)The medical care costs of obesity: an instrumental variables approach J Health Econ. 31 219-230
[5]  
Barton P(2013)Cost-utility analysis conducted alongside randomized controlled trials: are economic end points considered in sample size calculations and does it matter? Clin Trials. 10 43-53
[6]  
Jowett S(2011)Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting BMJ. 342 d1548-1396
[7]  
Sutton AJ(2016)Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants Lancet. 387 1377-268
[8]  
Starr M(2015)An economy of scales: a selective review of obesity’s economic causes, consequences, and solutions J Health Econ. 43 244-142
[9]  
Dominiak L(2015)Clinical trials provide essential evidence, but rarely offer a vehicle for cost-effectiveness analysis Value Health. 18 141-350
[10]  
Aizcorbe A(2015)Davey Smith G. Mendelian randomization: new applications in the coming age of hypothesis-free causality Annu Rev Genomics Hum Genet. 16 327-48